Study of GSK1363089 in Metastatic Gastric Cancer

Neoplasms, Gastrointestinal Tract Clinical Trial

Official title:
A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects With Metastatic Gastric Cancer

Status Completed

Clinical Trial Summary

This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in metastatic gastric carcinoma.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00725712
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 2
Start date	March 2007
Completion date	November 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00526669` - Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib	Phase 2
Active, not recruiting	`NCT00680901` - LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib	Phase 3
Completed	`NCT00486954` - Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer	Phase 3